CompletedNCT05536297
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
PHASE3 · 278 planned enrolment
- Countries listed
- 17
- Registry update
- May 18, 2026
Registry Intervention View
avacincaptad pegol
Trial registrations containing the exact intervention label avacincaptad pegol.
Exact registry label · Not reported
6 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
4 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT03362190
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
PHASE2 · 64 planned enrolment
- Countries listed
- 3
- Registry update
- June 10, 2025
CompletedNCT02686658
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
PHASE2 · PHASE3 · 286 planned enrolment
- Countries listed
- 7
- Registry update
- June 10, 2025
TerminatedNCT05571267
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
PHASE2 · 1 planned enrolment
- Countries listed
- 0
- Registry update
- March 13, 2025
CompletedNCT00709527
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
PHASE1 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- March 10, 2025
CompletedNCT00950638
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
PHASE1 · 47 planned enrolment
- Countries listed
- 1
- Registry update
- March 10, 2025